Innovent Biologics, Inc.
IVBXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $125,990,940 | $54,736,224 | $55,555,782 | $55,159,692 |
| - Cash | $9,540,139 | $7,508,185 | $8,165,264 | $10,052,095 |
| + Debt | $3,379,316 | $2,831,043 | $3,348,728 | $3,620,529 |
| Enterprise Value | $119,830,117 | $50,059,082 | $50,739,246 | $48,728,126 |
| Revenue | $5,953,094 | $5,469,597 | $3,952,291 | $3,504,538 |
| % Growth | 8.8% | 38.4% | 12.8% | – |
| Gross Profit | $4,599,532 | $4,152,238 | $2,857,902 | $2,479,452 |
| % Margin | 77.3% | 75.9% | 72.3% | 70.7% |
| EBITDA | $1,029,578 | -$231,413 | -$248,864 | -$741,753 |
| % Margin | 17.3% | -4.2% | -6.3% | -21.2% |
| Net Income | $834,321 | $297,989 | -$392,620 | -$888,764 |
| % Margin | 14% | 5.4% | -9.9% | -25.4% |
| EPS Diluted | 0.49 | 0.18 | -0.24 | -0.56 |
| % Growth | 172.2% | 175% | 57.1% | – |
| Operating Cash Flow | $313,765 | $1,502,658 | -$215,634 | $770,701 |
| Capital Expenditures | -$102,576 | -$266,152 | -$699,513 | -$521,484 |
| Free Cash Flow | $211,189 | $1,236,506 | -$915,147 | $249,217 |